FDA Misbranding Letter to Tuyo Health Signals Tighter Scrutiny of Compounded GLP-1 Claims

Tuyo Health, Inc. has received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) for misbranding compounded semaglutide and tirzepatide products through false or misleading promotional claims on its website. The September 9, 2025, enforcement action targets specific language equating compounded formulations with FDA-approved brands such as Wegovy, Ozempic, Zepbound, and Mounjaro. For 503A and 503B compounders operating in the GLP-1 space, this letter reinforces the agency's position that "same active ingredient" claims cross a regulatory line under FDCA sections 502(a) and 502(bb), and it foreshadows a compliance environment where promotional language will face increasing federal scrutiny.

The FDA's Office of Compounding Quality and Compliance (OCQC) reviewed Tuyo Health's website in August 2025 and identified three specific claims: "Same active as Wegovy and Ozempic," "Same active ingredient as Zepbound and Mounjaro," and "With compounded semaglutide, you get the same trusted active ingredient as in brand-name medications." The agency determined that these statements imply equivalence with FDA-approved products, which compounded drugs are not. Under section 502(a) of the FDCA [21 U.S.C. § 352(a)], a drug is misbranded if its labeling is false or misleading in any particular. Section 502(bb) [21 U.S.C. § 352(bb)] extends this standard to advertising and promotion of compounded drugs specifically. The introduction of such misbranded products into interstate commerce constitutes a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)], and receipt in interstate commerce of misbranded drugs also violates section 301(c) [21 U.S.C. § 331(c)].

The letter explicitly states that the cited violations "do not represent an exhaustive list of misbranding violations," a standard enforcement caveat that nonetheless signals the agency may be building a broader case or monitoring for additional infractions. Tuyo Health, based in Miami, Florida, was given 15 working days from receipt to provide a written response to OCQC describing corrective actions taken, including steps to prevent recurrence. The FDA warned that failure to adequately address violations "may result in legal action without further notice, including, without limitation, seizure and injunction."

For compounding pharmacies and outsourcing facilities marketing GLP-1 receptor agonist formulations, this enforcement action carries direct operational implications. The distinction between sharing an active pharmaceutical ingredient and claiming therapeutic equivalence with an approved product is one the FDA is now actively policing in digital channels. Quality assurance and regulatory affairs teams at compounding operations should audit all website content, patient-facing materials, and promotional copy for language that could be construed as implying sameness with branded products. Labeling and advertising compliance under FDCA 502(a) and 502(bb) requires that compounded drug claims be evaluated not only for literal accuracy but for the overall impression conveyed to consumers and prescribers.

The warning letter was issued by CDER and delivered via electronic mail with read/delivery receipt requested. It was directed to Tuyo Health, Inc. dba Tuyo Health at 382 NE 191st ST PMB 353681, Miami, FL 33179. The full text of the warning letter is available on the FDA's warning letters database.